Asthma management

References

• Centers for Disease Control and Prevention. Asthma mortality and hospitalization among children and young adults: United States, 1980–1993. MMWR 1996; 45(17):350–3
   PubMedGoogle Scholar
• Adams PF, Marano MA. Current estimates from the National Health Interview Survey. Vital Health Stat 1995; 10:94
   Google Scholar
• Burt CW, Knapp DE. Ambulatory care visits for asthma: United States, 1993–94. Advance data from Vital and Health Statistics of the Centers for Disease Control and Prevention/National Center for Health Statistics. Hyattsville, Md: Dept of Health and Human Services, 1996; No.217:1–18
   Google Scholar
• Zeiger RS, Heller S, Mellon MH, et al. Facilitated referral to asthma specialist reduces relapses in asthma emergency room visits. J Allergy Clin Immunol 1991; 87(6): 1160–8 [Erratum, J Allergy Clin Immunol 1992;90(2):278]
   PubMed Web of Science ®Google Scholar
• Freund DA, Stein J, Hurley R, et al. Specialty differences in the treatment of asthma. J Allergy Clin Immunol 1989; 84(3):401–6
   Google Scholar
• Charlton I, Jones K, Bain J. Delay in diagnosis of childhood asthma and its influence on respiratory consultation rates. Arch Dis Child 1991; 66(5):633–5
   PubMedGoogle Scholar
• Jones KP, Charlton IH, Middleton M, et al. Targeting asthma care in general practice using a morbidity index. BMJ 1992; 304(6838):1353–6
   Google Scholar
• National Asthma Education Program expert panel report. Guidelines for the diagnosis and management of asthma. Bethesda: Dept of Health and Human Services, 1991; NIH publication No.91-3042
   Google Scholar
• National Asthma Education Program expert panel report. Executive summary: guidelines for the diagnosis and management of asthma. Bethesda: Dept of Health and Human Services, 1991; NIH publication No.91-3042A
   Google Scholar
• National Heart, Lung, and Blood Institute. Global initiative for asthma. 1995; DHHS publication No.95-3659
   Google Scholar
• Kendrick AH, Higgs CM, Whitfield MJ, et al. Accuracy of perception of severity of asthma: patients treated in general practice. BMJ 1993; 307(6901):422–4
   PubMedGoogle Scholar
• Krahn M. Issues in the cost-effectiveness of asthma education. Chest 1994; 106(4 Suppl):264–9S
   Google Scholar
• Ignacio-Garcia JM, Gonzalez-Santos P. Asthma self-management education program by home monitoring of peak expiratory flow. Am J Respir Crit Care Med 1995; 151(2 Pt 1):353–9
   PubMedGoogle Scholar
• National Analysts. Asthma agent survey. Philadelphia: Booz-Allen & Hamilton, Inc, 1990
   Google Scholar
• Bone RC. A step care strategy for asthma management. J Respir Dis 1988; 9:104–17
   Google Scholar
• Lang DM. Inhaled steroids are underutilized in urban areas of high asthma mortality. (Abstr) J Allergy Clin Immunol 1994: 93:246
   Google Scholar
• Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma: report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis 1993; 148(4 Pt 2):S1–26
   Google Scholar
• Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142(4):832–6
   PubMed Web of Science ®Google Scholar
• Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126(3):177–83
   PubMed Web of Science ®Google Scholar
• Kaliner MA. Inhaled corticosteroids for chronic asthma. Am Fam Physician 1990; 42:1609–16
   Google Scholar
• Garbe E, LeLorier J, Boivin JF, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277(9):722–7
   PubMedGoogle Scholar
• Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995; 98(2):196–208
   PubMed Web of Science ®Google Scholar
• Suissa S, Biais L, Ernst P. Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 1994; 7(9):1602–9
   Google Scholar
• Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335(12):841–7
   PubMed Web of Science ®Google Scholar
• Aubier M. Effect of theophylline on diaphragmatic and other skeletal muscle function. J Allergy Clin Immunol 1986; 78(4 Pt 2):787–92
   Google Scholar
• Sullivan P, Bekir S, Jaffar Z, et al. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994; 343(8904):1006–8 [Erratum, Lancet 1994;343(8911):1512]
   PubMed Web of Science ®Google Scholar
• Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med 1996; 334(21):1380–8
   Google Scholar
• Finnerty JP, Wood-Baker R, Thomson H, et al. Role of leukotrienes in exercise-induced asthma: inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 1992; 145(4 Pt 1):746–9
   Google Scholar
• Taylor IK, O'Shaughnessy KM, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337(8743):690–4
   Google Scholar
• Glass M, Snader LA, Israel E. Effect of the inhaled LTD4-receptor antagonist, ICI 204,219, on cold-air-induced bronchoconstriction in patients with asthma. (Abstr) J Allergy Clin Immunol 1994; 93:295
   Google Scholar
• Calhoun WJ, Lavins BJ, Glass M. Effect of ‘Accolate’ (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental bronchoprovocation (SBP) in patients with mild to moderate asthma. (Abstr) Am J Respir Crit Care Med 1995; 151:A42
   Google Scholar
• ACCOLATE Asthma Trialists Group. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150(3):618–23
   Google Scholar
• Zileuton Clinical Trial Group. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA 1996; 275(12):931–6
   Google Scholar
• Spector SL. Leukotriene inhibitors and antagonists in asthma. Ann Allergy Asthma Immunol 1995; 75(6 Pt 1):463–70, 473; quiz 473–4
   Google Scholar
• Reiss TF, Altman LC, Chervinsky P, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98(3):528–34
   PubMed Web of Science ®Google Scholar
• Lichey J, Hummel S, Beck E, et al. Effect of leukotriene antagonist Bay X 1005 versus placebo in patients with severe steroid dependent bronchial asthma. (Abstr) Am J Respir Crit Care Med 1995; 151:A377
   Google Scholar
• Yeung M, O'Connor SA, Parry DT, et al. Compliance with prescribed drug therapy in asthma. Respir Med 1994; 88(1):31–5
   Google Scholar
• Allegra L. Deliberate non-compliance due to dislike of medication. Eur Respir Rev 1995; 5:170–2
   Google Scholar
• Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994; 154(12):1349–52
   PubMed Web of Science ®Google Scholar